The Prognostic Impact of Hormone Receptors and c-erbB-2 in Pregnancy-Associated Breast Cancer and Their Correlation with BRCAI and Cell Cycle Modulators
Restricted accessResearch articleFirst published online April, 2003
The Prognostic Impact of Hormone Receptors and c-erbB-2 in Pregnancy-Associated Breast Cancer and Their Correlation with BRCAI and Cell Cycle Modulators
A population-based series of 122 patients with pregnancy-associated breast carcinomas was histologically revised and the relationship between hormone receptors, cerbB-2, BRCA1, p27, cyclin E, and cyclin D1 was studied. The 5-year overall survival was 41%; 70% had tumor size >20 mm; 72% had metastasized to regional lymph nodes; 95% were histologic grade II or III; 66% and 75% were negative for estrogen and progesterone receptor, respectively; and c-erbB-2 expression was high (44%). BRCA1 expression was reduced in 33% of the cases. The expression of p27, cyclin D 1, and cyclin E was low, 11%, 9%, and 16%, respectively. Cyclin D I was positively associated with the hormone receptors (p<0.01). In multivariate analysis, lymph node status, progesterone receptor, and c-erbB-2 were significant prognostic factors. In subdividing the group according to lymph node status, c-erbB-2 and progesterone receptor retained a prognostic significance in the node positive group only. In conclusion, pregnancy-associated breast carcinomas are aggressive tumors, with low expression of hormone receptors, BRCA1, p27, and cyclin E and DI, and high expression of c-erbB-2.
1. Wallack CK, Wolf JA, Denes AE, Glasgow G, Kumar B. Gestational carcinoma of the female breast. Curr Probl Cancer7:1-58, 1983
2.
2. Lethaby AE, O'Neill MA, Mason BH, Holdaway IM, Harvey VJ. Overall survival from breast cancer in women pregnant or lactating at or after diagnosis. Auckland Breast Cancer Study Group. Int J Cancer67:751-755, 1996
4. Bonnier P, Romain S, Dilhuydy JM, Bonichon F, Julien JP, Charpin C, Lejeune C, Martin PM, Piana L. Influence of pregnancy on the outcome of breast cancer: A case-control study. Int J Cancer72:720-727, 1997
5.
5. Tretli S, Kvalheim G, Thoresen S, Host H. Survival of breast cancer patients diagnosed during pregnancy or lactation. Br J Cancer58:382-384, 1988
6.
6. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL, Chodosh LA. The developmental pattern of BRCA1 expression implies a role in differentiation of the breast and other tissues. Nat Genet11:17-26, 1995
7.
7. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, HaugenStrano A, Swensen J, Miki Y, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science266:120-122, 1994
8.
8. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science266:66-71, 1994
9.
9. Chen Y, Chen CF, Riley DJ, Allred DC, Chen PL, VonHoff D, Osborne CK, Lee WH. Aberrant subcellular localization of BRCA1 in breast cancer. Science270:789-791, 1995
10.
10. Sherr CJ. Mammalian GI cyclins and cell cycle progression. Proc Assoc Am Physicians107:181-186, 1995
11.
11. Williamson EA, Dadmanesh F, Koeffler H. BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kipl). Oncogene21:3199-3206, 2002
12.
12. Nielsen NH, Emdin SO, Cajander J, Landberg G. Deregulation of cyclin E and D 1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene14:295-304, 1997
13.
13. van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP. Cyclin D 1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol150:705-711, 1997
14.
14. Geng Y, Whoriskey W, Park MY, Bronson RT, Medema RH, Li T, Weinberg RA, Sicinski P. Rescue of cyclin DI deficiency by knocking cyclin E. Cell97:767-777, 1999
15.
15. Nielsen NH, Amerlov C, Emdin SO, Landberg G. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer74:874-880, 1996
16.
16. Porter PL, Maloney T, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM. Expression of cell-cycle regulators p27kiPl and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med3:222-225, 1997
17.
17. Fantl V, Smith R, Brookes S, Dickson C, Peters G. Chromosome 11q13 abnormalities in human breast cancer [see comments]. Cancer Surv18:77-94, 1993
18.
18. Sicinski P, Weinberg RA. A specific role for cyclin Dl in mammary gland development. J Mammary Gland Biol Neoplasia2:335-342, 1997
19.
19. Elston CW, Ellis IO, Parham DM. Method for grading breast cancer [5]. J Clin Pathol46:189-190, 1993
20.
20. Pertschuk LP, Feldman JG, Kim YD, Braithwaite L, Schneider F, Braverman AS, Axiotis C. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ERID5 predicts breast cancer endocrine response more accurately than H222Spgamma in frozen sections or cytosol-based ligand-binding assays. Cancer77:2514-2519, 1996
21.
21. Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression in breast ductal carcinoma: Pathologic correlations and prognostic implications. Hum Pathol32:89-94, 2001
22.
22. De Potter CR, Quatacker J, Maertens G, Van Daele S, Pauwels C, Verhofstede C, Eechaute W, Roels H. The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer44:969-974, 1989
23.
23. Styles JM, Harrison S, Gusterson BA, Dean CJ. Rat monoclonal antibodies to the external domain of the product of the C-erbB-2 proto-oncogene. Int J Cancer45:320-324, 1990
24.
24. Miyamoto K, Fukutomi T, Asada K, Wakazono K, Tsuda H, Asahara T, Sugimura T, Ushijima T. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. Jpn J Clin Oncol32:79-84, 2002
25.
25. Elledge RM, Ciocca DR, Langone G, McGuire WL. Estrogen receptor, progesterone receptor, and HER2/neu protein in breast cancers from pregnant patients [see comments]. Cancer71:2499-2506, 1993
26.
26. Ishida T, Yokoe T, Kasumi F, Sakamoto G, Makita M, Tominaga T, Simozuma K, Enomoto K, Fujiwara K, Nanasawa T. Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation: analysis of case-control study in Japan. Jpn J Cancer Res83:1143-1149, 1992
27.
27. Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, Gullick WJ, Elston CW, Blamey RW. cerbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer63:439-443, 1991
28.
28. Thorpe SM, Rose C, Rasmussen BB, Mouridsen HT, Bayer T, Keiding N. Prognostic value of steroid hormone receptors: Multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res47:6126-6133, 1987
29.
29. Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. Ten-year pathologic and clinical prognostic discriminants. Cancer71:2507-2514, 1993
30.
30. Yang Q, Sakurai T, Mori I, Yoshimura G, Nakamura M, Nakamura Y, Suzuma T, Tamaki T, Umemura T, Kakudo K. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer92:54-60, 2001
31.
31. Yoshikawa K, Honda K, Inamoto T, Shinohara H, Yamauchi A, Suga K, Okuyama T, Shimada T, Kodama H, Noguchi S, Gazdar AF, Yamaoka Y, Takahashi R. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCAI-associated cases. Clin Cancer Res5:1249-1261, 1999
32.
32. Bogdani M, Teugels E, De-Greve J, Bourgain C, Neyns B, Pipeleers-Marichal M. Loss of nuclear BRCA1 localization in breast carcinoma is age dependent. Virchows Arch440:274-279, 2002
33.
33. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet9:444-450, 1995
34.
34. Bernard-Gallon DJ, Dechelotte P, Rio PG, Bignon YJ. Expression of human BRCA1 and BRCA2 proteins in lung from a fetus at 19 weeks' gestation. Int J Cancer82:771-773, 1999
35.
35. Chen CF, Li S, Chen Y, Chen PL, Sharp ZD, Lee WH. The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor. J Biol Chem271:32863-32868, 1996
36.
36. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod SA. Pregnancy and risk of early breast cancer in carriers of BRCAI and BRCA2. Lancet354:1846-1850, 1999
37.
37. Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A, Deng CX. Conditional mutation of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet22:37-43, 1999
38.
38. Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. BRCA1 mutations in a populationbased sample of young women with breast cancer [see comments]. N Engl J Med334:137-142, 1996
39.
39. Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA. BRCAI mutations and breast cancer in the general population: Analyses in women before age 35 years and in women before age 45 years with first-degree family history [see comments]. JAMA279:922-929, 1998
40.
40. Catzavelos C, Bhatacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, MoravaProtzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM. Decreased levels of the cell-cycle inhibitor p27KiPl protein: Prognostic implications in primary breast cancer. Nature Med3:227-230, 1997
41.
41. Tsuchiya A, Zhang GJ, Kanno M. Prognostic impact of cyclin-dependent kinase inhibitor p27kipl in node-positive breast cancer. J Surg Oncol70:230-234, 1999
42.
42. Nohara T, Ryo T, Iwamoto S, Gon G, Tanigawa N. Expression of cell-cycle regulator p27 is correlated to the prognosis and ER expression in breast carcinoma patients. Oncology60:94-100, 2001
43.
43. Barbareschi M, van-Tinteren H, Mauri FA, Veronese S, Peterse H, Maisonneuve P, Caffo O, Scaioli M, Doglioni C, Galligioni E, Dalla-Palma P, Michalides R. p27(kipl) expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer89:236-241, 2000
44.
44. Polyak K, Lee MH, Erdjument B, Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27Kipl, a cyclindependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell78:59-66, 1994
45.
45. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p2IWAF1 /CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA97:9042-9046, 2000
46.
46. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi GC, Lavin P, Draetta G, Pagano M, Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (Tla, b) invasive breast carcinomas. Cancer Res57:1259-1263, 1997
47.
47. Leong AC, Hanby AM, Potts HW, Tan DS, Skilton D, Ryder K, Harris WH, Liebmann RD, Barnes DM, Gillett CE. Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast. Int J Cancer89:26-31, 2000
48.
48. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res54:380-385, 1994
49.
49. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res54:1812-1817, 1994
50.
50. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D. Cyclin DI and prognosis in human breast cancer. Int J Cancer69:92-99, 1996
51.
51. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Overexpression of cyclinD 1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer98:415-418, 2002
52.
52. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244:707-712, 1989
53.
53. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science232:644-646, 1986
54.
54. Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE. Effects of oncogenic ErbB-2 on GI cell cycle regulators in breast tumour cells. Oncogene19:1647-1656, 2000
55.
55. Hulit J, Lee RJ, Russell RG, Pestell RG. ErbB-2-induced mammary tumor growth: The role of cyclin DI and p27Kipl. Biochem Pharmacol64:827-836, 2002
56.
56. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D 1 ablation. Nature411:1017-1021, 2001
57.
57. Bowe DB, Kenney NJ, Adereth Y, Maroulakou IG. Suppression of Neu-induced mammary tumor growth in cyclin Dl-deficient mice is compensated for by cyclin E. Oncogene21:291-298, 2002
58.
58. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GK, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG. Cyclin DI is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol20:672-683, 2000
59.
59. Bertheau P, Steinberg SM, Merino MJ. C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: Immunohistochemical analysis and clinicopathologic correlation. Hum Pathol29:323-329, 1998
60.
60. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D, McGuire WL. HER2/neu amplification predicts poor survival in nodepositive breast cancer. Cancer Res50:4332-4337, 1990
61.
61. Gusterson BA, Gullick WJ, Venter DJ, Powles TJ, Elliott C, Ashley S, Tidy A, Harrison S. Immunohistochemical localization of c-erbB-2 in human breast carcinomas. Mol Cell Probes1:383-391, 1987
